ARK Genomic Revolution ETF ARKG

Medalist Rating as of | See ARK Investment Hub

Morningstar’s Analysis ARKG

Will ARKG outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

ARK Genomic Revolution ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings ARKG

  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 58.5
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Twist Bioscience Corp

8.75 209M
Healthcare

10x Genomics Inc Ordinary Shares - Class A

8.73 209M
Healthcare

Tempus AI Inc Class A common stock

8.36 200M
Healthcare

Absci Corp

5.56 133M
Healthcare

CRISPR Therapeutics AG

5.22 125M
Healthcare

Guardant Health Inc

4.88 117M
Healthcare

Natera Inc

4.71 113M
Healthcare

Illumina Inc

4.69 112M
Healthcare

Eli Lilly and Co

3.92 94M
Healthcare

Beam Therapeutics Inc

3.69 88M
Healthcare

Sponsor Center